SNDX - Syndax Pharmaceuticals Inc Stock Price, Fair Value and News

24.49USD-0.14 (-0.57%)Market Closed

Market Summary

USD24.49-0.14

Market Closed

-0.57%

SNDX Alerts

1 major insider buys recently.

SNDX Stock Price

View Fullscreen

SNDX RSI Chart

SNDX Valuation

Market Cap

2.1B

Price/Earnings (Trailing)

-8.65

Price/Sales (Trailing)

13.61

Price/Free Cashflow

-10.16

SNDX Price/Sales (Trailing)

SNDX Profitability

Return on Equity

-48.92%

Return on Assets

-44.31%

Free Cashflow Yield

-9.85%

SNDX Fundamentals

SNDX Revenue

Revenue (TTM)

139.7M

SNDX Earnings

Earnings (TTM)

-240.6M

Earnings Growth (Yr)

-76.04%

Earnings Growth (Qtr)

0.1%

Breaking Down SNDX Revenue

Last 7 days

6.1%

Last 30 days

26.1%

Last 90 days

17.0%

Trailing 12 Months

13.9%

How does SNDX drawdown profile look like?

SNDX Financial Health

Current Ratio

8.93

SNDX Investor Care

Shares Dilution (1Y)

23.49%

Diluted EPS (TTM)

-3.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2021	1.5M	1.5M	13.5M	139.7M
2020	1.5M	1.5M	1.5M	1.5M
2019	1.5M	1.5M	1.5M	1.5M
2018	2.2M	2.3M	2.3M	1.5M
2017	1.2M	1.2M	1.2M	2.1M
2016	775.3K	923.5K	1.1M	1.2M
2015	0	0	0	627.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 for the treatment of KMT2A rearranged (KMT2Ar) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

CEO	Mr. Michael A. Metzger M.B.A.
WEBSITE	syndax.com
INDUSTRY	Biotechnology
EMPLOYEES	107

Syndax Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for Syndax Pharmaceuticals Inc? What does SNDX stand for in stocks?

SNDX is the stock ticker symbol of Syndax Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Syndax Pharmaceuticals Inc (SNDX)?

As of Thu Jul 25 2024, market cap of Syndax Pharmaceuticals Inc is 2.09 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SNDX stock?

You can check SNDX's fair value in chart for subscribers.

Is Syndax Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether SNDX is over valued or under valued. Whether Syndax Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Syndax Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SNDX.

What is Syndax Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, SNDX's PE ratio (Price to Earnings) is -8.7 and Price to Sales (PS) ratio is 13.61. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SNDX PE ratio will change depending on the future growth rate expectations of investors.